Journal article
Refining anti-inflammatory therapy strategies for bronchopulmonary dysplasia
I Rudloff, SX Cho, CB Bui, C McLean, A Veldman, PJ Berger, MF Nold, CA Nold-Petry
Journal of Cellular and Molecular Medicine | WILEY | Published : 2017
DOI: 10.1111/jcmm.13044
Abstract
Bronchopulmonary dysplasia (BPD) is a severe lung disease of preterm infants, which is characterized by fewer, enlarged alveoli and increased inflammation. BPD has grave consequences for affected infants, but no effective and safe therapy exists. We previously showed that prophylactic treatment with interleukin-1 receptor antagonist (IL-1Ra) prevents murine BPD induced by perinatal inflammation and hyperoxia. Here, we used the same BPD model to assess whether an alternative anti-inflammatory agent, protein C (PC), is as effective as IL-1Ra against BPD. We also tested whether delayed administration or a higher dose of IL-1Ra affects its ability to ameliorate BPD and investigated aspects of dr..
View full abstractGrants
Awarded by Baxter BioScience
Funding Acknowledgements
This study was supported by research grants from the Windermere and Marian E. Flack Foundations to A.V., from Baxter Bioscience to A.V. and P.J.B., from the Jack Brockhoff Foundation to M.F.N and C.A.N.P., by the Larkins and Victor Yu Fellowships by Monash University to M.F.N. and by the Victorian Government's Operational Infrastructure Support Program and a Future Leader Fellowship by the National Heart Foundation of Australia [CF14/3517] to C.A.N.P. The authors thank Nikeh Shariatian and Elizabeth Skuza for excellent technical assistance and acknowledge the facilities and scientific and technical assistance of Monash Histology Platform, Department of Anatomy and Developmental Biology, Monash University.